Danaher (NYSE:DHR) CAO Christopher Bouda Sells 7,598 Shares of Company Stock

Danaher Corporation (NYSE:DHR) CAO Christopher Bouda sold 7,598 shares of Danaher stock in a transaction that occurred on Wednesday, October 28th. The stock was sold at an average price of $234.56, for a total transaction of $1,782,186.88. Following the transaction, the chief accounting officer owned 9,107 shares in the company, valued at approximately $2,136,137.92. The trade was a 45.48% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this link.

Danaher Price Performance

Shares of NYSE:DHR opened at $236.77 on Friday. The company’s fifty day moving average is $218.59 and its two-hundred day moving average is $201.81. The company has a market cap of $166.58 billion, a P/E ratio of 38.75, a price-to-earnings-growth ratio of 2.94 and a beta of 0.76. Danaher Corporation has a 12-month low of $160.93 and a 12-month high of $242.80. The company has a quick ratio of 1.29, a current ratio of 1.63 and a debt-to-equity ratio of 0.45.

Danaher (NYSE:DHR) last issued its earnings results on Wednesday, October 21st. The conglomerate reported $2.11 EPS for the quarter, topping the consensus estimate of $1.92 by $0.19. Danaher had a return on equity of 11.17% and a net margin of 16.91%. The business had revenue of $6.55 billion during the quarter, compared to analysts’ expectations of $6.56 billion. During the same quarter last year, the firm posted $1.89 earnings per share. Danaher’s revenue was up 8.3% compared to the same quarter last year. Equities analysts expect that Danaher Corporation will post 8.59 earnings per share for the current fiscal year.

Danaher Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, October 30th. Investors of record on Wednesday, September 30th will be paid a $0.40 dividend. This represents a $1.60 annualized dividend and a yield of 0.7%. The ex-dividend date of this dividend is Wednesday, September 30th. Danaher’s dividend payout ratio is currently 26.19%.

Institutional Trading of Danaher

Several hedge funds and other institutional investors have recently modified their holdings of the company. BlackRock Inc. bought a new position in shares of Danaher during the 2nd quarter valued at $10,492,520,000. Jupiter Topco LLC acquired a new stake in shares of Danaher in the 2nd quarter valued at $1,456,317,000. Generation Investment Management LLP acquired a new stake in shares of Danaher in the 2nd quarter valued at $1,287,949,000. Bank of America Corp DE bought a new stake in Danaher in the second quarter worth $993,846,000. Finally, Legal & General Group Plc bought a new stake in Danaher in the second quarter worth $801,056,000. 79.05% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Several equities analysts have weighed in on DHR shares. Wall Street Zen raised Danaher from a “hold” rating to a “buy” rating in a research note on Monday. Royal Bank Of Canada increased their price target on shares of Danaher from $215.00 to $250.00 and gave the stock an “outperform” rating in a research report on Monday, October 5th. Robert W. Baird raised their price target on shares of Danaher from $246.00 to $254.00 and gave the stock an “outperform” rating in a report on Thursday, October 22nd. JPMorgan Chase & Co. boosted their price objective on shares of Danaher from $250.00 to $270.00 and gave the company an “overweight” rating in a research report on Thursday, October 22nd. Finally, TD Cowen upped their price objective on shares of Danaher from $255.00 to $270.00 and gave the company a “buy” rating in a research note on Thursday, October 22nd. Eighteen investment analysts have rated the stock with a Buy rating and five have assigned a Hold rating to the company’s stock. According to MarketBeat.com, Danaher presently has a consensus rating of “Moderate Buy” and a consensus price target of $242.91.

Danaher Company Profile

Danaher Corporation (NYSE: DHR) is a global science and technology company that develops products, services and solutions for the life sciences, biotechnology and diagnostics markets. Its offerings help researchers, pharmaceutical and biotechnology companies, healthcare providers and other organizations conduct scientific research, develop and manufacture medicines, and diagnose disease.

The company operates through businesses that provide bioprocessing equipment and technologies, laboratory instruments, consumables, analytical tools and clinical diagnostic systems.